胃印戒细胞癌的临床病理特征与外科综合治疗

doi:10.16139/j.1007-9610.2021.01.017

摘要/Abstract

中图分类号:

R735.2

梅郁, 朱正纲. 胃印戒细胞癌的临床病理特征与外科综合治疗[J]. 外科理论与实践, 2021, 26(01): 79-83.

MEI Yu, ZHU Zhenggang. Gastric signet ring cell carcinoma: clinicopathology and surgical treatment combined with comprehensive therapy[J]. Journal of Surgery Concepts & Practice, 2021, 26(01): 79-83.

参考文献 35

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global Cancer Statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424.
[2]	Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin, 2016, 66(2):115-132.
[3]	Flejou JF. WHO classification of digestive tumors: the fourth edition[J]. Ann Pathol, 2011, 31(5 Suppl):S27-S31.
[4]	Taghavi S, Jayarajan SN, Davey A, et al. Prognostic significance of signet ring gastric cancer[J]. J Clin Oncol, 2012, 30(28):3493-3498.
[5]	Chon HJ, Hyung WJ, Kim C, et al. Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia[J]. Ann Surg, 2017, 265(5):946-953.
[6]	Kao YC, Fang WL, Wang RF, et al. Clinicopathological differences in signet ring cell adenocarcinoma between early and advanced gastric cancer[J]. Gastric Cancer, 2019, 22(2):255-263.
[7]	Jiang CG, Wang ZN, Sun Z, et al. Clinicopathologic characteristics and prognosis of signet ring cell carcinoma of the stomach: results from a Chinese mono-institutional study[J]. J Surg Oncol, 2011, 103(7):700-703.
[8]	Li C, Kim S, Lai JF, et al. Advanced gastric carcinoma with signet ring cell histology[J]. Oncology, 2007, 72(1-2):64-68.
[9]	Kang SH, Kim JS, Moon HS, et al. Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment rea-lly risky?[J]. Medicine, 2017, 96(33):e7532.
[10]	Pyo JH, Shin CM, Lee H, et al. A risk-prediction model based on lymph-node metastasis for incorporation into a treatment algorithm for signet ring cell-type intramucosal gastric cancer[J]. Ann Surg, 2016, 264(6):1038-1043.
[11]	Lee IS, Lee S, Park YS, et al. Applicability of endoscopic submucosal dissection for undifferentiated early gastric cancer: mixed histology of poorly differentiated adenocarcinoma and signet ring cell carcinoma is a worse predictive factor of nodal metastasis[J]. Surg Oncol, 2017, 26(1):8-12.
[12]	Zhao X, Cai A, Xi H, et al. Predictive factors for lymph node metastasis in early gastric cancer with signet ring cell histology: a meta-analysis[J]. ANZ J Surg, 2017, 87(12):981-986.
[13]	Chu YN, Mao T, Li XY, et al. Predictors of lymph node metastasis and differences between pure and mixed histologic types of early gastric signet-ring cell carcinomas[J]. Am J Surg Pathol, 2020, 44(7):934-942.
[14]	Abe S, Oda I, Suzuki H, et al. Short- and long-term outcomes of endoscopic submucosal dissection for undiffe-rentiated early gastric cancer[J]. Endoscopy, 2013, 45(9):703-707.
[15]	Kim MN, Kim HK, Shim CN, et al. Tumour size is rela-ted to the curability of signet ring cell early gastric cancer with endoscopic submucosal dissection: a retrospective single centre study[J]. Dig Liver Dis, 2014, 46(10):898-902.
[16]	Lee YM, Kang SH, Kim JS, et al. Subepithelial spread of early gastric signet ring cell carcinoma: how far they can reach?[J]. Dig Dis, 2020, 38(6):442-448.
[17]	Qi J, Zhang P, Wang Y, et al. Does total gastrectomy provide better outcomes than distal subtotal gastrectomy for distal gastric cancer? a systematic review and meta-analysis[J]. PloS One, 2016, 11(10):e0165179.
[18]	Arer IM, Yabanoglu H, Akdur A, et al. Total versus subtotal gastrectomy for signet ring cell carcinoma of the stomach[J]. J Coll Physicians Surg Pak, 2017, 27(10):616-620.
[19]	de Manzoni G, Verlato G, Bencivenga M, et al. Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer[J]. Eur J Surg Oncol, 2015, 41(4):534-540. doi: 10.1016/j.ejso.2015.01.023 pmid: 25707350
[20]	Chen L, Shi Y, Yuan J, et al. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients[J]. Med Oncol, 2014, 31(9):159-169. doi: 10.1007/s12032-014-0159-5 pmid: 25119501
[21]	Shu Y, Zhang W, Hou Q, et al. Prognostic significance of frequent CLDN18-ARHGAP26/6 fusion in gastric signet-ring cell cancer[J]. Nat Commun, 2018, 9(1):2447-2457.
[22]	Heger U, Sisic L, Nienhuser H, et al. Neoadjuvant therapy improves outcomes in locally advanced signet-ring-cell containing esophagogastric adenocarcinomas[J]. Ann Surg Oncol, 2018, 25(8):2418-2427.
[23]	Messager M, Lefevre JH, Pichot-Delahaye V, et al. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study[J]. Ann Surg, 2011, 254(5):684-693. doi: 10.1097/SLA.0b013e3182352647 pmid: 22005144
[24]	Heger U, Blank S, Wiecha C, et al. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?[J]. Ann Surg Oncol, 2014, 21(5):1739-1748.
[25]	Kim S, Fiteni F, Paget-Bailly S, et al. The impact of taxa-ne-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas[J]. J Hematol Oncol, 2015, 8:52.
[26]	Li Y, Ma FH, Xue LY, et al. Neoadjuvant chemotherapy vs. upfront surgery for gastric signet ring cell carcinoma: a retrospective, propensity score-matched study[J]. World J Gastroenterol, 2020, 26(8):818-827.
[27]	Charalampakis N, Nogueras Gonzalez GM, Elimova E, et al. The proportion of signet ring cell component in patients with localized gastric adenocarcinoma correlates with the degree of response to pre-operative chemoradiation[J]. Oncology, 2016, 90(5):239-247. doi: 10.1159/000443506 pmid: 27046280
[28]	Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J]. J Clin Oncol, 2012, 30(19):2327-2333.
[29]	Park SH, Sohn TS, Lee J, et al. Phase Ⅲ trial to compare adjuvant chemotherapy with capecitabine and cisplatin versus concurrent chemoradiotherapy in gastric cancer: final report of the adjuvant chemoradiotherapy in stomach tumors trial, including survival and subset analyses[J]. J Clin Oncol, 2015, 33(28):3130-3136.
[30]	Wei F, Lyu H, Wang S, et al. Postoperative radiotherapy improves survival in gastric signet-ring cell carcinoma: a SEER database analysis[J]. J Gastric Cancer, 2019, 19(4):393-407.
[31]	Lemoine N, Adenis A, Bouche O, et al. Signet ring cells and efficacy of first-line chemotherapy in advanced gastric or oesogastric junction adenocarcinoma[J]. Anticancer Res, 2016, 36(10):5543-5549.
[32]	Mariette C, Bruyere E, Messager M, et al. Palliative resection for advanced gastric and junctional adenocarcinoma: which patients will benefit from surgery?[J]. Ann Surg Oncol, 2013, 20(4):1240-1249.
[33]	Pernot S, Dubreuil O, Aparicio T, et al. Efficacy of a docetaxel-5FU-oxaliplatin regimen (TEFOX) in first-line treatment of advanced gastric signet ring cell carcinoma: an AGEO multicentre study[J]. Br J Cancer, 2018, 119(4):424-428.
[34]	Badgwell B, Blum M, Das P, et al. Phase Ⅱ trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma[J]. Ann Surg Oncol, 2017, 24(11):3338-3344 doi: 10.1245/s10434-017-6047-4 pmid: 28799004
[35]	Hotopp T. HIPEC and CRS in peritoneal metastatic gastric cancer - who really benefits?[J]. Surg Oncol, 2019, 28:159-166.

胃印戒细胞癌的临床病理特征与外科综合治疗

Gastric signet ring cell carcinoma: clinicopathology and surgical treatment combined with comprehensive therapy

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 35

相关文章 15

编辑推荐

Metrics

本文评价

[1]	谢吻, 梁怀予, 董磊, 袁菲, 王朝夫, 郭滟. 胰腺导管腺癌重要驱动基因突变与临床病理特征、预后间相关性的分析[J]. 诊断学理论与实践, 2022, 21(05): 581-587.
[2]	樊金芳, 沈依, 詹维伟, 陶玲玲, 李伟伟, 况李君, 周伟. 峡部甲状腺微小乳头状癌临床病理分析[J]. 外科理论与实践, 2021, 26(06): 528-531.
[3]	杨一娴, 倪仲馨, 夏蜀珺, 周伟, 詹维伟. 多灶性与单灶性甲状腺乳头状癌的临床病理特征及超声表现的比较[J]. 诊断学理论与实践, 2021, 20(02): 168-172.
[4]	王志威, 张晓晓, 王杰, 魏敏, 邵玉国, 籍敏, 杨莉, 何奇. 局部晚期乳腺癌患者腋窝淋巴结转移范围的影响因素分析[J]. 诊断学理论与实践, 2019, 18(2): 189-192.
[5]	高琛妮, 沈平雁, 潘晓霞, 徐耀文, 徐静, 胡晓帆, 张文, 谢静远, 任红, 陈晓农,. 16例冷球蛋白血症患者临床病理特点分析[J]. 内科理论与实践, 2019, 14(05): 298-302.
[6]	陈舒婕, 陈小松, 籍敏, 邵玉国, 沈坤炜, 何奇. 含微乳头成分的乳腺浸润性黏液癌的分析[J]. 外科理论与实践, 2019, 24(05): 440-445.
[7]	郝晓妍, 彭勋, 任光辉. 青年与老年乳腺癌病人临床病理特征比较及预后分析[J]. 外科理论与实践, 2019, 24(02): 168-170.
[8]	朱晓萍, 陈小松, 杨兴霞, 朱娟英. 不同年龄绝经前乳腺癌临床病理特征和辅助治疗方案选择[J]. 外科理论与实践, 2018, 23(06): 528-532.
[9]	陈赛蓉, 包家林, 赵纹芸, 许伟青,. 三阴性乳腺癌的临床病理特征分析[J]. 外科理论与实践, 2014, 19(02): 136-139.
[10]	刘冲, 安晓静, 石群立, 徐艳, 周航波, 马恒辉,. 肾脏神经鞘瘤一例报告伴文献复习[J]. 诊断学理论与实践, 2009, 8(06): 650-652.
[11]	章志坚, 韩少良, 朱冠保,. 早期胃癌的临床病理特征[J]. 外科理论与实践, 2008, 13(03): 249-250.
[12]	林言箴,尹浩然,朱正纲. 论胃癌外科综合治疗的发展前景[J]. 外科理论与实践, 2003, 8(01): 1-2.
[13]	金黑鹰,崔龙,孟荣贵,刘飞,冯跃,徐洪莲,黄炜,喻德洪,阎于悌,王金穗. 非典型遗传性非息肉病性结直肠癌临床病理特征(19个家系随访)[J]. 外科理论与实践, 2001, 6(06): 393-394.
[14]	陈汝福,邹声泉. 肝门部胆管癌临床病理特征及诊治现状[J]. 外科理论与实践, 2000, 5(04): 279-281.
[15]	尹浩然,朱正纲,林言箴. 进展期胃癌外科综合治疗的方法与步骤[J]. 外科理论与实践, 2000, 5(03): 134-135.